Revalesio announces initiation of Asthma Phase I/IIa trial

Date: May 19, 2010

Revalesio Corporation, a private biotechnology company, today announced the initiation of a Phase I/IIa trial of RNS60, the first product in a new class of anti-inflammatory drugs, to determine the safety and tolerability of RNS60 in healthy volunteers and mild asthmatics as measured by spirometry.

Read More…

Revalesio announces Investigational New Drug approval for novel treatment of asthma

Date: May 7, 2010

Tacoma, WA– Revalesio Corporation announced today that the FDA approved its plans to study RNS60, a novel anti-inflammatory product. Revalesio will conduct the Phase I/IIa clinical trial in partnership with Stanford University and West Coast Clinical Trials.

Read More…